Capnellene derivatives have recently been identified as possible treatments for neuropathic pain. Neuropathic pain is characterized by damage to peripheral or central nerves that results in pathological nociceptive transmission, the neuronal process that responds noxious stimuli. Two capnellene derivatives Δ-capnellene-8β,10α-diol and 8α-acetoxy-Δ-capnellene-10α-ol demonstrate potential as analgesics capable of attenuating neuropathic pain. These compounds have been shown in vivo to reduce two proteins that mediate inflammation, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). In vivo, Δ-capnellene-8β,10α-diol inhibited hyperalgesia behavior in the mouse model for neuropathic pain in a dose-dependent manner. Additionally, treatment with Δ-capnellene-8β,10α-diol inhibited the up-regulation of immunoreactivity in the mouse model, specifically targeting the production of COX-2. Unlike many non-steroidal anti-inflammatory drugs, Δ-capnellene-8β,10α-diol is advantageous in its selectivity for the COX isoenzyme COX-2, avoiding many of the gastrointestinal side effects associated with the inhibition of COX-1. This fact would allow for the administration of Δ-capnellene-8β,10α-diol in higher doses, potentially offering significant relief from neuropathic pain.